iCarbonX is a pioneering company that focuses on new biological discoveries by leveraging multi-omics research, biological data integration and analysis, machine intelligence, and multi-dimensional full life cycle data integration and computational analysis. These methodologies have effectively propelled the basic scientific discoveries of partners in the field of life science and health. iCarbonX provides robust support for the innovation and development of partners in the areas of disease prevention, diagnosis, treatment, and healthcare. Simultaneously, it accelerates the development of next-generation diagnostic technology, vaccine research and development, biomedicine, and other related industries.
The company's founder, Jun Wang, has been recognized for his contributions to the field and was selected in Clarivate Analytics’ list of “Highly Cited Researchers 2018”. He emphasizes the importance of a holistic approach to understanding diseases, stating, "To have a deep understanding of diabetes, we should dig into diet, intestinal microbes, genes, proteins, metabolics–not just insulin."
iCarbonX operates a large laboratory with world-class construction standards. It has established a one-stop research and development system of genomics, proteomics, immunomics, microbiome, metabolomics, cell platform, and instrument platform. This system facilitates the research of life science and clinical problems. The one-stop multi-omics laboratory and integrated data analysis platform can fully exploit the interactions at all levels of biology to fully demonstrate the underlying biological mechanisms and improve the success rate of discovering biomarkers and targets of biomedical significance.
Since 2019, iCarbonX has refocused on opening its multi-omics laboratory and integrated data analysis platform to empower biopharmaceutical and biotechnology companies. This initiative aims to jointly promote the development of new diagnostic products, vaccines, and pharmaceutical products.